

COPY OF PAPERS ORIGINALLY FILED

3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 2 2 2002

TECH CENTER 1600/2900

Charles L. Sawyers et al. Serial No.: 10/022, 115

Filed:

December 14, 2001

Docket:

30435.53USD2

Title:

MICE MODELS OF HUMAN PROSTATE CANCER PROGRESSION

CERTIFICATE UNDER 37 CFR 1,8

I hereby certify that this paper or fee is being deposited with the United States Postal as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on April 30, 2002.

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8.

Information Disclosure Statement (37 C.F.R. §1.97 (d))

Form 1449 (Information Disclosure Statement)

Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

35 No. Arroyo Parkway, Suite 60 Pasadena, California 91103 (626)395-7801

Name: Sarah B. Adriano

Reg. No.: 34,470 Initials: SBA

OTPE COM H

COPY OF PAPERS ORIGINALLY FILED

RECEIVED

MAY 2 2 2002

TECH CENTER 1600/2900

Applicant:

Charles L. Sawyers, et al.

Examiner:

Not yet assigned

Serial No.:

10/022,115

Group Art Unit:

1632

Filed:

December 14, 2001

Docket No.:

30435.53USD2

Title:

MICE MODELS OF HUMAN PROSTATE CANCER PROGRESSION

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on April 30, 2002.

By: Richelle Ann Donningo

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(d))

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- Liu, A.Y., et al., "Prostatic Cell Lineage Markers: Emergence of BCL2⁺ Cells of Human
 Prostate Cancer Xenograft LuCaP 23 Following Castration," *Int. J. Cancer*, 65:85-89 (1996).
- Lubaroff, D.M., et al., "Survival of Human Prostate Carcinoma, Benign Hyperplastic Prostate
 Tissues, and IL-2 Activated Lymphocytes in SCID Mice," *The Prostate*, 27:32-41 (1995).
- Wainstein, M.A., et al., "CWR22: Androgen-Dependent Xenograft Model Derived from a
 Primary Human Prostatic Carcinoma," Cancer Research, 54:6049-6052 (1994).
- o Pretlow, T.G., et al., "Xenograft of Primary Human Prostatic Carcinoma," *Journal of the National Cancer Institute*, 85(5):394-398 (1993).

Charles L. Sawyers, et al. Serial No. 10/022,115 Filed: December 14, 2001

Page 2

 Pretlow, T.G., et al., "Transplantation of Human Prostatic Carcinoma into Nude Mice in Matrigel," Cancer Research, 51:3814-3817 (1991).

- Perez-Stable, et al., Cancer Research, Vol. 57, Pages 900-906. (March 1, 1997).
- Sato, et al., Journal of Urology, Vol. 155: 5, Page 338A (May 4, 1996).
- van Weerden, et al., American Journal of Pathology, Vol. 149: 3, Pages 1055-1062.
 (September 1996).

This statement should be considered because it is submitted before the mailing date of the first Office Action on the merits. The present application is a divisional application of U.S. Serial No. 09/567,202, filed May 8, 2000. The art cited in the enclosed PTO Form 1449 were previously of record in the parent application, i.e., U. S. Serial No. 09/567, 202 and are not provided herewith in accordance with 37 C.F.R. §1.98(d).

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Charles L. Sawyers, et al. Serial No. 10/022,115 Filed: December 14, 2001

Page 3

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

No fees are due in connection with the filing of this IDS. If, however, a fee is deemed necessary, please charge any additional fees to Deposit Account No. 50-0306.

with the

Respectfully submitted,

Sarah B. Adriano

Registration No. 34,470

Attorney for Applicants

Mandel & Adriano

35 N. Arroyo Parkway, Suite 60

Pasadena, CA 91103

(626) 395-7801

I hereby certify that this paper is being deposited with the Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Richelle Ann Domingo I

ate

MAY 2 0 200 FORM 1449°

Docket Number 30435.53USD1 09/567, 20

Applicant

(Use several sheets if necessary)

Filing Date May 8, 2000

Group Art Unit 1632

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
TVT		Liu, A. Y., et al., "Prostatic Cell Lineage Markers: Emergence of BCL2+ Cells of Human Prostate
		Carticer Xenograft LuCaP 23 Following Castration," Int. J. Cancer, 65:85-89 (1996)
1		Lubaroff, D. M., et al., "Survival of Human Prostate Carcinoma, Benjon Hyperplastic Prostate
		Tissues, and IL-2-Activated Lymphocytes in SCID Mice," The Prostate, 27:32-41 (1995)
		Wainstein, M. A., et al., "CWR22: Androgen-Dependent Xenograft Model Derived from a Primary
		Human Prostatic Carcinoma," Cancer Research, 54:6049-6052 (1994).
		Pretlow, T. G., et al., "Xenografts of Primary Human Prostatic Carcinoma." Journal of the National
		Cancer Institute, 85(5):394-398 (1993).
1		Pretlow, T. G., et al., "Transplantation of Human Prostatic Carcinoma into Nude Mice in Matrigel,"
	<u> </u>	Cancer Research, 51:3814-3817 (1991).
		Perez-Stable et al., Cancer Research, Vol. 57, Pages 900-906. (March 1, 1997).
₩	-	Sato et al., Journal of Urology, Vol. 155: 5, Page 338A. (May 4, 1996).
TNT		van Weerden et al., American Journal of Pathology, Vol. 149: 3, Pages 1055-1062. (September 1996).
		COPY OF PAPERS
		ORIGINALLY FILED
		SCENED
		3002
		MAX 2 2 200
		MAY 8 2 2002 MAY 8 2 2002
		TECH CENTER 1600/290
		ILO.
·····		
00 apro o o o o o o o o o o o o o o o o o o	,	2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

EXAMINER Thaie

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE